Several phase III clinical trials have reported improved progression-free survival (PFS) in NSCLC patients harbouring EGFR mutations who are treated with gefitinib or erlotinib compared to those treated with standard chemotherapy [22–27]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.